text: Yo, our knowledge of multiple sclerosis
  Has grown, man, it's a real progression
  New therapies and compounds in the game
  Clinical tests, approvals, it's never the same
  
  Alemtuzumab, the antibody in the mix
  Depletes CD52+ cells, that's the trick
  Keeps the lymphoid precursor cells intact
  Phase II and III trials, the data's exact
  
  Comparing interferon-β-1a, the active one
  Clinical efficacy and safety, all done
  T and B cells, they reconstitute different
  A potential mode of action, that's significant
  
  Watch out for secondary autoimmune conditions
  Linked to treatment, it's a real mission
  Regulatory agencies giving positive opinions
  This new drug's gonna treat relapsing-remitting, no illusions
  
  Multiple sclerosis, we're expanding our scope
  With this new drug, we ain't gonna mope
  Enlarging our therapeutic arsenal, it's the plan
  Active relapsing-remitting, we're gonna take a stand